{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Spero Therapeutics, Inc.
Spero Therapeutics Hits 52-Week Low at $1.42 Amid Market Challenges
Spero Therapeutics, Inc. has reached a new 52-week low of USD 1.42, reflecting a modest one-year performance of 0.7%. With a market capitalization of USD 135 million, the company has a P/E ratio of 14.00 and a price-to-book ratio of 2.29, alongside a return on equity of 15.96%.
Spero Therapeutics Hits New 52-Week Low at $1.51 Amid Market Turmoil
Spero Therapeutics, Inc. has reached a new 52-week low of USD 1.51, down from a high of USD 3.08, highlighting its stock volatility. With a market cap of USD 135 million, a P/E ratio of 14.00, and a return on equity of 15.96%, the company reflects a unique financial structure in the biotechnology sector.
Is Spero Therapeutics, Inc. technically bullish or bearish?
As of July 17, 2025, Spero Therapeutics, Inc. shows a mildly bullish trend with daily moving averages indicating positivity, despite mixed signals from weekly indicators and a bearish RSI, while outperforming the S&P 500 with a year-to-date return of 94.17%.
Is Spero Therapeutics, Inc. overvalued or undervalued?
As of March 27, 2025, Spero Therapeutics, Inc. is considered overvalued with a risky valuation grade due to its high Price to Book Value of 4.13, negative EV to EBIT and EV to EBITDA ratios, and a low Return on Equity of -203.20%, despite a strong year-to-date stock return of 94.17%.
Is Spero Therapeutics, Inc. overvalued or undervalued?
As of March 27, 2025, Spero Therapeutics, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics, including a Price to Book Value of 4.13 and an ROE of -203.20%, despite a strong year-to-date stock performance of 184.47%.
Is Spero Therapeutics, Inc. technically bullish or bearish?
As of June 11, 2025, the trend is bullish with moderate strength, supported by a bullish MACD, moving averages, and OBV, although bearish RSI readings suggest potential weakness.
Who are in the management team of Spero Therapeutics, Inc.?
As of March 2022, the management team of Spero Therapeutics, Inc. includes Dr. Milind Deshpande (Independent Chairman), Dr. Ankit Mahadevia (President and CEO), and several Independent Directors: Dr. Jean-Francois Formela, Mr. Scott Jackson, Mr. John Pottage, Ms. Cynthia Smith, and Mr. Frank Thomas. They oversee the company's strategic direction and governance.
What does Spero Therapeutics, Inc. do?
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections. As of March 2025, it reported net sales of $5 million and a net loss of $14 million, with a market cap of $162.14 million.
How big is Spero Therapeutics, Inc.?
As of Jun 18, Spero Therapeutics, Inc. has a market capitalization of 162.14 million and reported net sales of 28.31 million with a net profit of -69.77 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
